487 related articles for article (PubMed ID: 30937470)
41. Dosing vancomycin in the super obese: less is more.
Crass RL; Dunn R; Hong J; Krop LC; Pai MP
J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.
Economou CJP; Kielstein JT; Czock D; Xie J; Field J; Richards B; Tallott M; Visser A; Koenig C; Hafer C; Schmidt JJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2018 Aug; 52(2):151-157. PubMed ID: 29526606
[TBL] [Abstract][Full Text] [Related]
43. Population Pharmacokinetic Analysis of Gentamicin in Pediatric Extracorporeal Membrane Oxygenation.
Moffett BS; Morris J; Galati M; Munoz FM; Arikan AA
Ther Drug Monit; 2018 Oct; 40(5):581-588. PubMed ID: 29957666
[TBL] [Abstract][Full Text] [Related]
44. Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.
Rainkie D; Ensom MH; Carr R
Paediatr Drugs; 2015 Jun; 17(3):245-53. PubMed ID: 25813682
[TBL] [Abstract][Full Text] [Related]
45. A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C.
Lu JJ; Chen M; Lv CL; Zhang R; Lu H; Cheng DH; Tang SY; Liu TT
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):535-546. PubMed ID: 32304024
[TBL] [Abstract][Full Text] [Related]
46. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.
He CY; Ye PP; Liu B; Song L; van den Anker J; Zhao W
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0089721. PubMed ID: 34339268
[TBL] [Abstract][Full Text] [Related]
47. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
Zelenitsky S; Rubinstein E; Ariano R; Iacovides H; Dodek P; Mirzanejad Y; Kumar A;
Int J Antimicrob Agents; 2013 Mar; 41(3):255-60. PubMed ID: 23312606
[TBL] [Abstract][Full Text] [Related]
48. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
[TBL] [Abstract][Full Text] [Related]
49. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study.
Villanueva RD; Talledo O; Neely S; White B; Celii A; Cross A; Kennedy R
J Trauma Acute Care Surg; 2019 Nov; 87(5):1164-1171. PubMed ID: 31464871
[TBL] [Abstract][Full Text] [Related]
50. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.
Chung J; Oh JM; Cho EM; Jang HJ; Hong SB; Lim CM; Koh YS
Anaesth Intensive Care; 2011 Nov; 39(6):1030-7. PubMed ID: 22165354
[TBL] [Abstract][Full Text] [Related]
51. Phenobarbital population pharmacokinetics across the pediatric age spectrum.
Moffett BS; Weingarten MM; Galati M; Placencia JL; Rodman EA; Riviello JJ; Kayyal SY
Epilepsia; 2018 Jul; 59(7):1327-1333. PubMed ID: 29897629
[TBL] [Abstract][Full Text] [Related]
52. Applicability of hemodialysis clearance parameter for vancomycin therapeutic drug monitoring during continuous hemodiafiltration in an infant.
Shiohira H; Isagawa S; Yamada S; Sunagawa S; Nakamatsu M; Yonaha F; Hokama N; Fujita J; Nakamura K
Pharmazie; 2018 Dec; 73(12):737-739. PubMed ID: 30522560
[TBL] [Abstract][Full Text] [Related]
53. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus.
Mei Q; Ye Y; Zhu YL; Cheng J; Yang HF; Liu YY; Li HR; Li JB
Int J Antimicrob Agents; 2015 Jun; 45(6):652-6. PubMed ID: 25813394
[TBL] [Abstract][Full Text] [Related]
54. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.
Sridharan K; Abbasi MY; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647
[TBL] [Abstract][Full Text] [Related]
55. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
56. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF).
Kirwan M; Munshi R; O'Keeffe H; Judge C; Coyle M; Deasy E; Kelly YP; Lavin PJ; Donnelly M; D'Arcy DM
Crit Care; 2021 Dec; 25(1):443. PubMed ID: 34930430
[TBL] [Abstract][Full Text] [Related]
57. Population Pharmacokinetics of Vancomycin Under Continuous Renal Replacement Therapy Using a Polymethylmethacrylate Hemofilter.
Yamazaki S; Tatebe M; Fujiyoshi M; Hattori N; Suzuki T; Takatsuka H; Uchida M; Suzuki T; Ishii I
Ther Drug Monit; 2020 Jun; 42(3):452-459. PubMed ID: 31913865
[TBL] [Abstract][Full Text] [Related]
58. Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Clin Pharmacokinet; 2020 Mar; 59(3):327-334. PubMed ID: 31471789
[TBL] [Abstract][Full Text] [Related]
59. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
60. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.
Masich AM; Kalaria SN; Gonzales JP; Heil EL; Tata AL; Claeys KC; Patel D; Gopalakrishnan M
Pharmacotherapy; 2020 Mar; 40(3):211-220. PubMed ID: 31957057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
